Allogene Therapeutics, Inc. Earnings Per Share (Basic)
Allogene Therapeutics, Inc. (ALLO) reported Earnings Per Share (Basic) of -$0.13 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-12
- Allogene Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.13.
- Allogene Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.18.
- Allogene Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.17.
- Allogene Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.19.
- Allogene Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$0.87.
- Allogene Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$1.32.
- Allogene Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$2.09.
- Allogene Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$2.38.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.13 10-Q · filed 2026-08-12 | -$0.30 10-Q · filed 2026-08-12 | -$0.47 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.65 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2026-03-31 | -$0.18 10-Q · filed 2026-05-13 | -$0.35 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.54 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.77 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2025-12-31 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.36 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.87 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$0.19 10-Q · filed 2025-11-06 | -$0.42 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.70 10-Q · filed 2025-11-06 | -$0.98 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2025-06-30 | -$0.23 10-Q · filed 2026-08-12 | -$0.51 10-Q · filed 2026-08-12 | -$0.79 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.11 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2025-03-31 | -$0.28 10-Q · filed 2026-05-13 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.88 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.22 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2024-12-31 | -$0.28 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.60 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.95 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.32 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | -$0.32 10-Q · filed 2025-11-06 | -$0.66 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$1.04 10-Q · filed 2025-11-06 | -$1.54 derived: net income ÷ weighted average shares · filed 2026-04-30 | ||||
| 2024-06-30 | -$0.35 10-Q · filed 2025-08-13 | -$0.73 10-Q · filed 2025-08-13 | -$1.23 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.61 derived: net income ÷ weighted average shares · filed 2026-04-30 | ||||
| 2024-03-31 | -$0.38 10-Q · filed 2025-05-13 | -$0.89 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.27 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.79 derived: net income ÷ weighted average shares · filed 2026-04-30 | ||||
| 2023-12-31 | -$0.51 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.88 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.41 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$2.09 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | -$0.37 10-Q · filed 2024-11-07 | -$0.90 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$1.58 10-Q · filed 2024-11-07 | -$1.55 10-Q · filed 2023-11-02 | -$2.25 derived: net income ÷ weighted average shares · filed 2024-11-07 | |||
| 2023-06-30 | -$0.54 10-Q · filed 2024-08-07 | -$0.53 10-Q · filed 2023-08-02 | -$1.23 10-Q · filed 2024-08-07 | -$1.21 10-Q · filed 2023-08-02 | -$1.90 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$2.49 derived: net income ÷ weighted average shares · filed 2024-11-07 | ||
| 2023-03-31 | -$0.69 10-Q · filed 2024-05-13 | -$0.68 10-Q · filed 2023-05-03 | -$1.37 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$1.95 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$2.51 derived: net income ÷ weighted average shares · filed 2024-11-07 | |||
| 2022-12-31 | -$0.67 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.26 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.82 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$2.38 10-K/A · filed 2024-03-14 | -$2.32 10-K · filed 2023-02-28 | |||
| 2022-09-30 | -$0.59 10-K · filed 2024-03-14 | -$0.58 10-Q · filed 2022-11-02 | -$1.15 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.70 10-K · filed 2024-03-14 | -$1.67 10-Q · filed 2022-11-02 | -$1.71 derived: net income ÷ weighted average shares · filed 2024-03-14 | ||
| 2022-06-30 | -$0.56 10-K · filed 2024-03-14 | -$0.52 10-Q · filed 2022-08-09 | -$1.12 10-K · filed 2024-03-14 | -$1.09 10-Q · filed 2022-08-09 | -$1.12 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.69 derived: net income ÷ weighted average shares · filed 2024-03-14 | ||
| 2022-03-31 | -$0.56 10-K · filed 2024-03-14 | -$0.56 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.13 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.65 derived: net income ÷ weighted average shares · filed 2024-03-14 | ||||
| 2021-12-31 | $0.00 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$0.57 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.09 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.34 10-K/A · filed 2024-03-14 | -$1.89 10-K · filed 2022-02-23 | |||
| 2021-09-30 | -$0.57 10-Q · filed 2022-11-02 | -$1.10 derived: net income ÷ weighted average shares · filed 2022-11-02 | -$1.35 10-Q · filed 2022-11-02 | -$2.37 derived: net income ÷ weighted average shares · filed 2024-03-14 | ||||
| 2021-06-30 | -$0.53 10-Q · filed 2022-08-09 | -$0.78 10-Q · filed 2022-08-09 | -$1.80 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$2.33 derived: net income ÷ weighted average shares · filed 2024-03-14 | ||||
| 2021-03-31 | -$0.25 10-Q · filed 2022-05-04 | -$1.28 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.80 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$2.34 derived: net income ÷ weighted average shares · filed 2024-03-14 | ||||
| 2020-12-31 | -$1.04 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.56 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$2.11 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$2.63 10-K/A · filed 2024-03-14 | -$2.08 10-K · filed 2022-02-23 | |||
| 2020-09-30 | -$0.52 10-Q · filed 2021-11-04 | -$1.05 derived: net income ÷ weighted average shares · filed 2021-11-04 | -$1.55 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | -$0.53 10-Q · filed 2021-08-04 | -$1.03 10-Q · filed 2021-08-04 | ||||||
| 2019-12-31 | -$1.83 10-K · filed 2022-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |